Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Many non-label or general-market statements are not supported by the provided FDA label excerpts. Several drug-specific safety/administration/monitoring details are either missing specificity (e.g., dose dependence) or not supported by the provided label text (e.g., generic substitution, pricing, lab periodicity wording). Some adverse effects are broadly consistent (hot flashes, breast pain/tenderness) but alignment is limited by numerous unsupported assertions and omissions.
Category Scores
Accurate Statements
Bicalutamide is used in the treatment of prostate cancer.
INDICATIONS AND USAGE (Stage D2 metastatic prostate carcinoma of the prostate; combination with an LHRH analog).
Bicalutamide is typically used as an anti-androgen therapy.
12.1 Mechanism of Action (non-steroidal androgen receptor inhibitor).
Common side effects linked to bicalutamide (anti-androgen therapy) can include hot flashes.
6.1 Clinical Trials Experience (hot flashes 53% in combination with an LHRH analog).
Common side effects linked to bicalutamide can include breast tenderness or breast enlargement.
5.3 Gynecomastia and Breast Pain (gynecomastia and breast pain reported).
Unsupported Statements
Bicalutamide is sold as an oral medicine under its generic name, bicalutamide.
Not supported by the provided FDA label excerpts (no product marketing/generic naming statements).
Bicalutamide is available under brand names in some markets.
Not supported by the provided FDA label excerpts.
Generic availability of bicalutamide depends on the country’s drug approval and marketplace.
Not supported by the provided FDA label excerpts.
Bicalutamide is commonly used in combination with other prostate cancer treatments when androgen suppression is needed.
Provided label excerpts specify combination with an LHRH analog for CASODEX 50 mg; they do not support 'other prostate cancer treatments' beyond LHRH analogs.
The exact dose and schedule of bicalutamide depend on the specific indication and the prescriber’s plan.
Label excerpts provide a specific recommended dose/schedule for CASODEX 50 mg with an LHRH analog; they do not state dose/schedule depends on prescriber plan.
Prescriptions for prostate cancer commonly use fixed daily dosing with tablets taken by mouth.
Not supported by the label excerpts (general practice statement).
Generic medicines are designed to be therapeutically equivalent to the reference product.
Not supported by the provided FDA label excerpts.
Generic medicines must have the same active ingredient as the reference product.
Not supported by the provided FDA label excerpts.
Generic medicines must meet regulatory standards for bioequivalence.
Not supported by the provided FDA label excerpts.
Differences between bicalutamide products usually come down to tablet strength, excipients, and how the medicine is packaged, not the active drug.
Not supported by the provided FDA label excerpts.
Common side effects linked to bicalutamide can include decreased libido.
Not supported by the provided label excerpts (no decreased libido listed).
Common side effects linked to bicalutamide can include erectile dysfunction.
Not supported by the provided label excerpts (no erectile dysfunction listed).
Patients may experience fatigue.
Not supported by the provided label excerpts.
Patients may experience gastrointestinal symptoms.
Not supported by the provided label excerpts.
Serious reactions with bicalutamide are less common but can occur.
The label excerpts describe serious adverse events but do not support this general 'less common' characterization.
In many places, pharmacists can substitute a generic product for the brand if it is approved as interchangeable/bioequivalent and the prescription allows substitution.
Not supported by the provided FDA label excerpts (legal/pharmacy policy not included).
Some clinicians request "dispense as written" to avoid changes in manufacturer.
Not supported by the provided FDA label excerpts.
If patients switch bicalutamide products, they should ask whether it is the same strength and whether any monitoring is needed.
Label excerpts do not address switching products or patient instructions about substitution/monitoring after switching.
Patients taking bicalutamide should seek medical advice promptly for symptoms that could signal a serious reaction.
General advice not supported by the provided label excerpts.
Signs of liver problems with bicalutamide can include yellowing of the skin or eyes.
Label excerpt specifies jaundice as a criterion for discontinuation but does not frame it as 'seek medical advice promptly' or list patient-sign guidance beyond discontinuation thresholds.
Signs of liver problems with bicalutamide can include dark urine.
Not supported by the provided label excerpts.
Signs of liver problems with bicalutamide can include significant fatigue with other symptoms.
Not supported by the provided label excerpts.
Clinicians may order periodic labs for patients taking bicalutamide depending on the regimen and risk factors.
Label excerpts specify specific liver enzyme measurement timing for hepatic warnings; 'depending on regimen and risk factors' is not directly stated in that way.
Generic bicalutamide is usually cheaper than the brand product.
Not supported by the provided FDA label excerpts.
Exact pricing of generic bicalutamide varies by country, insurance status, and pharmacy.
Not supported by the provided FDA label excerpts.
Generic bicalutamide is typically available through regulated pharmacies with a prescription.
Not supported by the provided FDA label excerpts.
Online vendors for bicalutamide should be avoided unless they are clearly licensed and operate under your country’s pharmacy rules.
Not supported by the provided FDA label excerpts.
Contradictions
Low
AI Statement
CASODEX 150 mg daily is not approved for use alone or with other treatments.
Label Reference
14.2 Safety Data from Clinical Studies using CASODEX 150 mg (CASODEX 150 mg daily is not approved for use either alone or with other treatments).
Important Omissions
Indication specificity: CASODEX 50 mg daily is indicated in combination with an LHRH analog for Stage D2 metastatic carcinoma of the prostate; CASODEX 150 mg daily is not approved alone or with other treatments. The response did not include these label-specific dose/indication constraints.
Importance:
Moderate
Dose administration details from the label (one 50 mg tablet once daily, morning or evening, with or without food; take at the same time each day; missed dose instructions).
Importance:
Moderate
Hepatic monitoring instructions: measure serum transaminases prior to starting, at regular intervals for first four months, and periodically thereafter; discontinue if jaundice or ALT >2x ULN.
Importance:
High
Key drug interaction warning: PT/INR monitoring and anticoagulant dose adjustment with coumarin anticoagulants.
Importance:
High
Safety issue listing in label: postmarketing reports of interstitial lung disease (some fatal) and photosensitivity; response did not mention these.
Importance:
Moderate
Use in specific populations: contraindicated in pregnant women due to fetal harm and not indicated for females; response did not mention these population restrictions.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several statements are unsupported by the provided label excerpts, and important label-specific safety and administration details (liver monitoring schedule/criteria, coumarin anticoagulant monitoring, and pregnancy/female contraindication) are omitted or not specified. This reduces on-label accuracy for safety-relevant guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Safety-relevant label content is largely omitted or generalized, and multiple non-label market/pharmacy/generic-substitution statements are included without support from the provided FDA excerpts.
Suggested Improvement
Restrict claims to the provided label excerpts: state the specific indication and CASODEX 50 mg dosing with LHRH analog, include label-required hepatic lab monitoring timing and discontinuation criteria, include coumarin anticoagulant PT/INR monitoring language, and avoid general marketplace/generic-substitution/pricing claims unless they are present in the label.